[A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole]

Gan To Kagaku Ryoho. 2021 Oct;48(10):1259-1263.
[Article in Japanese]

Abstract

Background: In step with the aging of the Japanese population, late recurrence of hormone receptor positive (HR+) breast cancer occurring especially beyond 20 years after the initial diagnosis has been recognized as not rare anymore, as it has been occurring at a constant rate lately. The administration of an aromatase inhibitor with a CDK4/6 inhibitor has become the gold standard in Japan for cases of recurring HR+ breast cancer without severe visceral metastasis.

Case: A 73- year-old woman was diagnosed by chance with late recurrence of HR+ breast cancer 21 years after undergoing radical resection followed by adjuvant anastrozole for 5 years for stage Ⅲb right breast cancer. Asymptomatic multiple bone metastases on her ribs and sternum with bilateral lung metastasis and malignant effusion all disappeared while she was on a year- long administration of anastrozole and an optimal dose of abemaciclib(100 mg bid). However, because of the Grade 3 digestive adverse event that occurred at approximately 1 year of treatment, she could only maintain the treatment for up to 13 months. After then, no recurrence has been detectable for 6 months so far.

Conclusion: CDK4/6 inhibitors, in combination with anastrozole, will play a pivotal role in the initial approach to elderly patients with HR+ late recurrence as a chemotherapy- free strategy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aminopyridines
  • Anastrozole / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Aromatase Inhibitors / therapeutic use
  • Benzimidazoles
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / surgery
  • Female
  • Hormones / therapeutic use
  • Humans
  • Neoplasm Recurrence, Local / drug therapy
  • Nitriles / therapeutic use

Substances

  • Aminopyridines
  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Benzimidazoles
  • Hormones
  • Nitriles
  • Anastrozole
  • abemaciclib